Cognitive therapy for depression in tuberculosis treatment: protocol for multicentre pragmatic parallel arm randomised control trial with an internal pilot

Nishani Fonseka, Zohaib Khan, Martyn Lewis, Zeeshan Kibria, Fayaz Ahmad, Muhammad Firaz Khan, Mian Ul-Haq, Zia Ul-Haq, Noor Sanauddin, Mahnoor Majid, Maryiam Rahim, Farooq Naeem, Mirrat Butt, Saadia Ashraf, Ivan Komproe, Christian Mallen, Ian Kellar, Ghasem Yadegarfar, Abbie Milner, Saima SheikhSaeed Farooq*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction and objectives There is an unmet need to develop high-quality evidence addressing tuberculosis (TB)-related mental health comorbidity, particularly in the context of lower-middle-income countries. This study aims to examine the effectiveness and cost-effectiveness of cognitive behavioural therapy (CBT) versus enhanced treatment as usual (ETAU) in improving depressive symptoms in people with TB and comorbid depression, enhancing adherence with anti-TB treatment (ATT) and its implementation in the real-world setting of Pakistan. Methods We will conduct a pragmatic parallel arm randomised control trial with an internal pilot. A brief psychological intervention based on CBT has been developed using a combination of qualitative and ethnographic studies. The inbuilt pilot trial will have a sample size of 80, while we plan to recruit 560 (280 per arm) participants in the definitive trial. Participants who started on ATT within 1 month of diagnosis for pulmonary and extrapulmonary TB or multidrug resistant TB (MDR-TB) and meeting the criteria for depression on Patient Health Questionnaire-9 (PHQ-9) will be randomised with 1:1 allocation to receive six sessions of CBT (delivered by TB healthcare workers) or ETAU. Data on the feasibility outcomes of the pilot will be considered to proceed with the definitive trial. Participants will be assessed (by a blinded assessor) for the following main trial primary outcomes: (1) severity of depression using PHQ-9 scale (interviewer-administered questionnaire) at baseline, weeks 8, 24 and 32 postrandomisation and (2) ATT at baseline and week 24 at the end of ATT therapy. Ethics and dissemination Ethical approval has been obtained from Keele University Research Ethics Committee (ref: 2023-0599-792), Khyber Medical University Ethical Review Board (ref: DIR/KMU-EB/CT/000990) and National Bioethics Committee Pakistan (ref: No.4-87/NBC-998/23/587). The results of this study will be reported in peer-reviewed journals and academic conferences and disseminated to stakeholders and policymakers.

Original languageEnglish
Article numbere083483
Number of pages14
JournalBMJ Open
Volume14
Issue number6
DOIs
Publication statusPublished - 17 Jun 2024

Bibliographical note

Publisher Copyright:
© 2024 BMJ Publishing Group. All rights reserved.

Funding

The CONTROL programme of research is funded through the National Institute for Health and Care Research (NIHR), UK (grant number NIHR201773).

FundersFunder number
National Institute for Health and Care Research (NIHR), UKNIHR201773

    Keywords

    • Depression & mood disorders
    • MENTAL HEALTH
    • Tuberculosis

    Fingerprint

    Dive into the research topics of 'Cognitive therapy for depression in tuberculosis treatment: protocol for multicentre pragmatic parallel arm randomised control trial with an internal pilot'. Together they form a unique fingerprint.

    Cite this